Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Хирургические инфекции кожи и мягких тканей

Литература

  1. Белобородов В.Б. Современные принципы применения левофлоксацина в лечении инфекций кожи и мягких тканей. Consilium medicum. 2009; №1: 38-42.
  2. Белькова Ю.А., Козлов Р.С., Кречикова О.И. и др. Эффективность и безопасность местного использования комбинации бацитрацина и неомицина в сравнении с хлорамфениколом в терапии неосложнённых хирургических инфекций кожи и мягких тканей у взрослых амбулаторных пациентов. Клин Микробиол Антимикроб Химиотер. 2013; 15:131-142.
  3. Гельфанд Б.Р., Мартынов А.Н., Гурьянов В.А., Шипилова О.С. Профилактика стресс-повреждений верхнего отдела желудочно-кишечного тракта у больных в критических состояниях. Хирургия Consilium medicum. 2003; прил. 2: 16-20.
  4. Гельфанд Б.Р. и др. Профилактика стресс-язв у больных в критических состояниях. Методические рекомендации РАСХИ. 2004.
  5. Дехнич А.В., Данилов А.И. Даптомицин: обзор фармакологических, клинических и микробиологических параметров. Клиническая микробиология и антимикробная химиотерапия. 2010; 12 (4).
  6. Дибиров М.Д. Пролежни. Профилактика и лечение. Методическое пособие. М.: МАИ. 2013.
  7. Дибиров М.Д. Диабетическая ангиопатия в монографии Сосудистая хирургия. М.: ГЭОТАР Медиа. 2014.
  8. Дибиров М.Д., Гаджимуратов Р.У., Лебедев В.В., Терещенко С.А. Выбор антибактериальной терапии в лечении гнойных осложнений синдрома диабетической стопы. Инфекции в хирургии. 2013; 11 (2).
  9. Ерюхин И.А., Гельфанд Б.Р., Шляпников С.А. Хирургические инфекции. СПб, 2003.
  10. Ефименко Н.А., Гучев И.А., Сидоренко С.В. Инфекции в хирургии. Фармакотерапия и профилактика. Смоленск, 2004.
  11. Земляной А.Б. Гнойно-некротические формы синдрома диабетической стопы. Патогенез, диагностика, клиника, лечение. Автореф. дисс. … д-ра мед. наук. 2003.
  12. Земляной А.Б., Юсупов И.А., Кисляков В.А. Состояние цитокиновой системы при гнойно-некротических и рецидивирующих гнойно-некротических осложнениях синдрома диабетической стопы и возможности иммуномодуляции. Трудный пациент. 2011; 10: 36-43.
  13. Козлов Р.С., Голуб А.В. Стратегия использования антимикробных препаратов как попытка ренессанса антибиотиков. Клин Микробиол Антимикроб Химиотер. 2011; 13: 322-334.
  14. Козлов Р.С., Сивая О.В., Шпынев К.В. и соавт. Антибиотикорезистентность Streptococcus pyogenes в России: результаты многоцентрового проспективного исследования ПеГАС-I. Клин. микробиол. антимикроб. химиотер. 2005; 7: 154-166.
  15. Кубышкин В.А., Шишин К.В. Эрозивно-язвенное поражение верхних отделов желудочно-кишечного тракта в раннем послеоперационном периоде. Хирургия Consilium medicum. 2004; 1: 17-20.
  16. Научный отчет о результатах исследования антибиотикорезистентности бактериальных возбудителей нозокомиальных инфекций в отделениях с интенсивным использованием антибиотиков в стационарах России (РеВАНШ). Научно-исследовательский институт антимикробной химиотерапии. Смоленск, 2009.
  17. Никитин А.В. Цефтаролин фозамил – цефалоспориновый антибиотик широкого спектра действия для лечения внебольничных пневмоний и осложненных инфекций кожи и подкожной клетчатки. Антибиотики и химиотерапия. 2011; 56: 7-8.
  18. Практическое руководство по антиинфекционной химиотерапии / под ред. Л.С. Страчунского, Ю.Б. Белоусова, С.Н. Козлова. Смоленск: МАКМАХ, 2007.
  19. Светухин А.М., Цветков В.О., Земляной А.Б., Молчанов В.В. Нерешенные проблемы диагностики и лечения тяжелой анаэробной инфекции мягких тканей. В кн. «Неотложная медицина в мегаполисе. Материалы второго международного форума. Москва, 20-21 апреля 2006» С. 130-131.
  20. Справочник по антимикробной терапии / под ред. Р.С. Козлова, А.В. Дехнича. Смоленск: 2013.
  21. Стратегия и тактика применения антимикробных средств в лечебных учреждениях России. Российские национальные рекомендации. М.: Боргес, 2012.
  22. Хачатрян Н.Н., Дизенгоф И.М., Смирнов Г.Г. Антибактериальная терапия в комплексном лечении гнойной инфекции кожи и мягких тканей при сопутствующем ВИЧ-инфицировании. Хирургия. 2008; 4: 24-28.
  23. Хачатрян Н.Н., Чупалов М.О. Послеоперационные осложнения: современный взгляд на профилактику и лечение. Хирургическая практика. 2013; 4.
  24. Хирургические инфекции кожи и мягких тканей. Российские национальные рекомендации. М.: Боргес, 2009.
  25. Хирургические инфекции: практическое руководство / под ред. И.А. Ерюхина, Б.Р. Гельфанда, С.А. Шляпникова. М.: Литтерра, 2006.
  26. Цветков В.О., Молчанов В.В. Проблема клинической диагностики и дифференциальной диагностики некротизирующей инфекции мягких тканей (НИМТ). Инфекции в хирургии. 2010; 8 (1): 47.
  27. Шляпников С.А. Хирургические инфекции мягких тканей – старая проблема в новом свете. Инфекции в хирургии. 2003; 1 (1): 14-21.
  28. Abrahamian F.M., Goldstein E.J. Microbiology of animal bite wound infections. Clin Microbiol Rev. 2011; 24: 231-246.
  29. Ahrenholz D.H. Necrotizing soft-tissue infections. Surg Clin North Am. 1988; 68(1): 199-214.
  30. American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. Clinical Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients. J Parenter Enteral Nutr. 2009; 33: 255-259.
  31. Anaya D.A., Dellingert E.P. Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis. 2007; 44 : 705-710.
  32. Harris A.D., Calfee D.P., Salgado C.D. et al. Strategies to prevent Methicillin-Resistant Staphylococcus aureus transmission and Infection in acute care hospitals: Update Infection control and Hospital Epidemiology. 2014; 35 (2): 108-133.
  33. Bahebeck J., Sobgui E., Loic F., Nonga B.N., Mbanya J.C., Sosso M. Limb-threatening and life-threatening diabetic extremities: clinical patterns and outcomes in 56 patients. J Foot Ankle Surg. 2010; 49(1): 43-46.
  34. Bartholomew C.F., Jones A.M. Human bites: a rare risk factor for HIV transmission. AIDS. 2006; 20: 631-632.
  35. White B., Seaton R.A. Complicated skin and soft tissue infections: literature review of evidence for experience with daptomycin. Infection and Drug Resistance. 2011; 4: 115-127.
  36. Bilton B.D., Zibari G.B., McMillan R.W. et al. Aggressive surgical management of necrotizing fasciitis serves to decrease mortality: a retrospective study. Am Surg. 1998; 64: 397-400.
  37. Bisno A.L., Stevens D.L. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996; 334: 240-245.
  38. Bozzetti F., Forbes A. The ESPEN clinical practice guidelines on Parenteral nutrition: present status and perspectives for future research. Clin Nutr. 2009; 28: 359-364.
  39. Braga M., Ljungqvist O., Soeters P. et al. ESPEN guidelines on parenteral nutrition: Surgery. Clin Nutr. 2009; 28: 378-386.
  40. Burchard K.W., McManus A.T., Bohnen J. et al. A Review of Necrotizing Soft-Tissue Infections. Sepsis. 1998; 2: 79-87.
  41. Carmelli Y. Strategies for managing today's infections. Clin Microbiol Infect. 2008; 14 Suppl 3: 22-31.
  42. Carmeli Y., Lidji S.K., Shabtai E., Navon-Venezia S., Schwaber M.J. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study. Diagn Microbiol Infect Dis. 2011;70 (3): 367-372.
  43. Carratala J., Roson B., Fernandez-Sabe N. et al. Factors associated with complications and mortality in adult patients hospitalized for infectious cellulitis. Eur J Clin Microb Infect Dis. 2003; 22: 151-157.
  44. Classen D.C., Evans R.S., Pestotnik S.L. et al The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med. 1992; 326: 281-286.
  45. Cline K.A., Turnbull T.L. Clostridial myonecrosis. Ann Emerg Med. 1985; 14: 459-466.
  46. Corey G.R., Stryewski M.E. New rules for clinical trials of patients with acute bacterial skin and skin-structure infections: do not ley the perfect be the enemy of the good. Clin Infect Dis. 2011; Suppl 7: S469-476.
  47. Cruse P.J.E. Wound infections: epidemiology and clinical characteristics. CT: Appleton and Lange, 1988.
  48. Currie B.J. Group A streptococcal infections of the skin: molecular advances but limited therapeutic progress. Curr Opin Infect Dis. 2006; 19: 132-138.
  49. Leaper D., Noy B. Surgical site infection a European perspective of incidence and economic burden. Int Wound J. 2004; 1: 247-273.
  50. Leaper D., JMcBrain A., Kramer A.et al Healthcare associated infection: novel strategies and antimicrobial implants to prevent surgical site infections. Review Ann R Coll Surg Engl. 2010; 92.
  51. Farrell D.J., Castanheira M., Mendes R.E. et al. In Vitro Activity of Ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumonia: A review of published studies and the AWARE Surveillance Program (2008-2010). Clinical Infectious Diseases. 2012; 55 (S3): S206-214.
  52. Stevens D.L., Bisno A.L., Chambers H.F. et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft tissue Infections: 2014 Update by the Infectious Diseases Society of America. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.
  53. Anderson D.J., Podgorny K., Berrios-Torres S.I. et al. Strategies to prevent Surgical Site Infections in Acute Care Hospitals: 2014 Update. Infection control and Hospital Epidemiology. 2014; 35 (Suppl 2): S66-89.
  54. Diem E. Infections in burns. 7th European congress of clinical microbiology and infectious diseases. Vienna, Austria. March 26-30, 1995, abst. 77.
  55. DiNubile M.J., Lipsky B.A. Complicated infections of skin and skin structure infections: When infection is more than skin deep. J Antimicrob Chemother. 2004; 53: 37-50.
  56. Drusano G.L. Early endpoints for acute bacterial skin and skin structure infections. Antimicrob Agents Chemotherapy. 2012; 56(5): 2221-2222.
  57. Dukic V.M., Lauderdale D.S., Wilder J. et al Epidemics of community-associated methicillin-resistant Staphylococcus aureus in the United States: a meta-analysis. PLoS One 2013, 8. E52722.
  58. Durandy A., Kaveri S.V., Kuijpers T.W. et al. Intravenous immunoglobulins: understanding properties and mechanisms. Clin Exp Immunol. 2009; 158 (Suppl 1): 2-13.
  59. Eady E.A., Cove J.H. Staphylococcal resistance revisited: Community-aquired methicillin-resistant Staphylococcus aureus, an emerging problem for the management of skin and soft tissue infections. Curr Opin Infect Dis. 2003; 16: 103-124.
  60. Edelberg J., Berger A., Weber D.J. et al. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin structure infections. Infect Control Hosp Epidemiol. 2008; 29: 160-169.
  61. Edelberg J., Taneja C., Zervos M. et al Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009; 14: 1516-1518.
  62. Edlich R.F., Cross C.L., Dahlstrom J.J., Long W.B. 3rd Modern concepts of the diagnosis and treatment of necrotizing fasciitis. J Emerg Med. 2010; 39(2): 261-265.
  63. Enzler M.J., Berbari E., Osmon D.R. Antimicrobial prophylaxis in adults. Mayo Clin Proc. 2011; 86: 686-701.
  64. File T.M.Jr. Necrotizing soft tissue infections. Current Infectious Disease Reports. 2003; 5(5): 407-415.
  65. File T.M., Stevens D.L. Contemporary diagnosis and management of skin and soft-tissue infections. 2ed. Newtown: Handbooks in Health Care Co.; 2007.
  66. Giordano P., Weber K., Gesin G., et al. Skin and skin structure infections: treatment with newer generation fluoroquinolones. Therapeutic and Clinical Risk Management. 2007; 3: 309-317.
  67. Goldstein E.J.C., Citron D.M., Hudspeth M., et al. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone, compared to the activities of 11 other oral antimicrobial agents against 390 aerobic and anaerobic bacteria isolated from human and animal bite wound skin and soft tissue infections in humans. Antimicrob Agents Chemother. 1997; 41: 1552-1557.
  68. Gonzalez-Ruiz A., Beiras-Fernanadez A., Lehmkuhl H. Clinical experience with daptomycin in Europe: the first 2,5 years. J Antimicrob Chemother. 2011; 66(4): 912-919.
  69. Graffunder E.M., Venezia R.A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother. 2002; 49: 999-1005.
  70. Horan T.C., Gaynes R.P., Martone W.J. et al. CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections. Infect Control Hosp Epidemiol. 1992; 13: 606-608.
  71. Howell-Jones R.S., Wilson M.J., Hill K.E. et al. A review of the microbiology, antibiotic usage and resistance in chronic skin wounds. J Antimicrob Chemother. 2005; 55: 143-149.
  72. International Consensus on the Diabetic Foot and the Practical Guidelines on the management and prevention of the Diabetic Foot. International Working Group on the Diabetic Foot (IWGDF). Consultative section of the IDF, may 2007.
  73. Iсigo J., Bermejo, B., Oronoz B. et al. Surgical site infection in general surgery: 5-year analysis and assessment of the National Nosocomial Infection Surveillance (NNIS) index. Cir Esp. 2006; 79: 224-230.
  74. Itani K.M., Dryden M.S., Bhattachatyya et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2010; 199 (6): 804-816.
  75. Jenkins T.C., Sabel A.L., Sarcone E.E. et al. Skin and soft tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis. 2010; 51: 895-903.
  76. Jofry L., Perret C., Abarca K. Recomendaciones para el manejo de mordeduras ocasionadas por animales. Rev Chil Infect. 2006; 23: 20-34/
  77. Aberg J.A., Gallant J.E., Ghanem K.G. et al. Primary Care Guidelines for the Management of Persons Infected with HIV: 2013 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Inf Dis. 2013; 58 (1): e1-e34.
  78. Ellingson K., Haas J., Aiello A.E. et al. Strategies to prevent healthcare-associated infections through hand hygiene. Infection control and Hospital Epidemiology. 2014; 35 (Suppl 2): S155-178.
  79. Keller P., Wille J., Ramshorst B. et al. Pressure ulcers in intensive care patients: a review of risks and prevention. Inten Care Med. 2002; 28(10): 1379-1388.
  80. Ki V., Rotstein C. Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care. Can J Infect Dis Med Microbiol. 2008; 19: 173-184.
  81. Klein E., Smith D.L., Laxminarayan R. Community-associated methicillin-resistant Staphylococcus aureus in outpatients, United States, 1999-2006. Emerg Infect Dis. 2009; 15(12): 1925-1930.
  82. Kozlov R.S., Krechikova O.I., Ivanchik N.V. et al. Etiology of Nosocomial Bacterial Infections in Russia. Rosnet Study Group. Proceedings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2008 Oct 25-28; Washington, DC, USA; p. 572, abst. K-4108.
  83. Kreymann K.G., de Heer G., Nierhaus A. et al. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007; (12): 2677-2685.
  84. Labreche M.J., Lee G.C., Attridge R.T. et al Treatment failure and costs in patients with methicillin resistant Staphylococcus aureus (MRSA) skin and soft tissue infections: a South Texas Ambulatory Research Network (STAPNet) study. J Am Board Fam Med. 2013; 26: 508-517.
  85. Lamont E., Seaton R.A., Macpherson M. et al Development of teicoplanin dosage guidelines for patients treated within an outpatient parenteral antibiotic therapy (OPAT) program. J Antinicrob Chemother. 2009; 64: 181-187.
  86. Lee C.Y., Kuo L.T., Peng K.T., Hsu W.H., Huang T.W., Chou Y.C.. Prognostic factors and monomicrobial necrotizing fasciitis: gram-positive versus gram-negative pathogens. BMC Infect Dis. 2011; 11: 5.
  87. Lipsky B.A., Berendt A.R., Cornia B.P. et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012; 54: e132-e173.
  88. Lipsky B.A., Moran G.J., Vo L. et al A prospective, multicenter, observational study of complicated skin and soft tissue infections in hospitalized patients: clinical characteristics, medical treatment, and outcomes. BMC Infect Dis. 2012; 12: 227.
  89. Liu C., Bayer A., Cosgrove S.E. et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011; 52: 1-38.
  90. Livesley N.J., Chow A.W. Infected pressure ulcers in elderly individuals. Clin Infect Dis. 2002; 35: 1390-1396.
  91. Locke J.B., et al. Novel Ribosomal Mutations in Staphylococcus aureus strains identified through Selection with the Oxazolidinones linezolid and Torezolid. Antimicro Agents Chemotherapy. 2009; 53 (12): 5265-5274.
  92. Magliacani G., Stella M., Calcagni M. Antimicrobial therapy problems in burn sepsis. Ann Medit Burns Club. 1994; 7 (2).
  93. Mangram A.J., Horan T.C., Pearson M.L. et al. Guideline for prevention of surgical site infection. Inf Contr Hosp Epidemiol. 1999; 20: 250-278.
  94. Patrick M.F., McKay C.M. et al. Increased incidence of skin and soft tissue infections and associated antimicrobial use: a population-based study. Antimicrob Agents Chemotherapy. 2012; 56: 6243-6249.
  95. Marwick C., Broomhall J., McCowan C. et al. Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients. J Antimicrob Chemother. 2011; 66: 387-397.
  96. May A.K., Stafford R.E., Bulger F.M. et al. Surgical Infection Society. Treatment of complicated skin and soft tissue infections. Surg Infect, 2009; 10: 467-499.
  97. Mediavilla J.R., Liang C., Matherma B., Kreiswirth B.N. Global epidemiology of community-associated methicillin resistant Staphylococcus aureus. Curr Opin Microbiol. 2012; 15: 588-595.
  98. Mitrevski M., Marrapodi R., Camponeschi A.et al. Immunomodulatory Effects of intravenous Immunoglobulins – Assembling a Jigsaw Puzzle. Intern. Trends in immunity. 2014; 2 (2): 67-73.
  99. Morales G., Picazo J.J., Baos E. et al Resistance to linezolid is mediated by the CRF gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis. 2010; 50(6): 821-825.
  100. Moran G.J., Krishnadasan A., Gorwitz R.J. et al. Methicillin-resistant Staphylococcus aureus infections among patients in the emergency department. N Engl J Med. 2006; 355: 666-674.
  101. Moran G.J., Fang E. et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin- structure infections (ESTABLISH-2): a randomized, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014, June: S1473-3099.
  102. Morgan M. Hospital management of animal and human bites. J Hosp Infect. 2005; 61: 1-10.
  103. Napolitano L.M. Early Appropriate parenteral antimicrobial treatment of complicated skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus. Surg Infect. 2008; 9: s17-s27.
  104. Nathwani D. Developments in outpatient parenteral antimicrobial therapy for Gram-positive infections in Europe, and the potential impact of daptomycin. J Antimicrob Chemotherapy. 2009; 64: 447-453.
  105. Nicodemo A.C., Robledo J.A., Jasovich A. et al. A multicentre, double-blind, randomized study comparing the e-cacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections. Int J Clin Pract. 1998; 52: 69-74.
  106. Nikulin A., Dekhnich A., Ivanchik N. et al. Susceptibility of Staphylococcus aureus in the community settings in Russia. 19th ECCMID, Helsinki, Finland, 16-19 May 2009.
  107. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulins. Ann Rev Immunol. 2008; 26: 513-533.
  108. Palacio J., Leуn M., Garcha-Belenguer S. Epidemiological aspects of dog bites. Gac Sanit. 2005; 19: 50-58.
  109. Pallin D.J., Binder W.D., Allen M.B. et al. Clinical trial: comparative effectiveness of cephalexin plus trimethropin-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clin Infect Dis. 2013; 56: 1754-1762.
  110. Amy P.J., Terribilini R.G., Ghobadi F., Azhir A., Barber A. Antibiotics for methicillin-resistant Staphylococcus aureus skin and soft tissue infections: the challenge of outpatient therapy. Am J Emerg Med. 2014; 32: 135138.
  111. PEDIS: Perfusion, Extent (size), Depth (tissue loss), Infection and Sensation. International Working Group on the Diabetic Foot. International Consensus on the Diabetic Foot. Brussels: International Diabetes Foundation, May, 2003.
  112. Pulgar S., Mehra M., Quintana A. et al. The epidemiology of hospitalized cases of skin and soft tissue infection in Europe. 18th European Congress of Clinical Microbiology and Infectious Diseases. Barcelona, Spain, 2008. Abstr. P821.
  113. Prokocimer P., De Anda C., Fang E. et al. Tedizolid phosphate versus linezolid for treatment of acute bacterial skin and skin structure infections. The ESTABLISH 1 Randomised Trial. JAMA. 2013; 309 (6): 559-569.
  114. Pruitt B.A. Jr, McManus A.T., Kim S.H. et al. Burn Wound Infections: current status. World J Surg. 1998; 22 (2): 135-145.
  115. Koerner R., Johnson A. Changes in the classification and management of skin and soft tissue infections. J Antimic Chemother. 2011; 66: 232-234.
  116. Stefani S., Chung D.R., Lindsay J.A. et al. Methicillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonization of typing methods. Int J Antivicrobial Agents. 2012; 39: 273-282.
  117. Sakonlas G., Moelering R.C. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis. 2008; 46 (Suppl 5): S360-367.
  118. Sanchez U., Peralta G. Necrotizing soft tissue infections: nomenclature and classification. Enferm Infecc Microbiol Clin. 2003; 21: 196-199.
  119. Sievert D.M., Rudrik J.T., Patel J.B. et al. Vancomycin-resistant Staphylococcus aureus in the United States. 2002-2006. Clin Infect Dis. 2008; 46 (5): 668-674.
  120. Singh G., Sinha S.K., Adhikary S. et al. Necrotising infections of soft tissues: a clinical profile. Eur J Surg. 2002; 168: 366-371.
  121. Sharpe J.N., Shively E.H., Polk H.C.Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005; 189: 425-428.
  122. Stefanopoulos P.K., Tarantzopoulou A.D. Facial bite wounds: management update. Int J Oral Maxillofac Surg. 2005; 34: 464-472.
  123. Steinberg J.P., Braun B.I., Hellinger W.C. et al. Timing of antimicrobial prophylaxis and the risk of surgical site infections: results from the Trial to Reduce Antimicrobial Prophylaxis Errors. Ann Surg. 2009; 259: 10-16.
  124. Stevens D.L., Aldape M.J., Bryant A.E. Life-threatening clostridial infections. Anaerobe. 2012; 18: 254-259.
  125. Stevens D.L., Bisno A.L., Chambers H.F. et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. ULR: http://www.idsociety.org/.
  126. Stevens D.L. Invasive group A streptococcus infections. Clin Infect Dis. 1992; 14: 2-11.
  127. Stone D.R., Gorbach S.L. Necrotizing fasciitis. The changing spectrum. Dermatol Clin. 1997; 15 (2): 213-220.
  128. Sutherland M.E., Meyer A.A. Necrotizing soft-tissue infections. Surg Clin North Am. 1994; 74: 591-607.
  129. Swartz M.N. Cellulitis. N Engl J Med. 2004; 350: 904-912.
  130. Taplitz R.A. Managing bite wounds. Currently recommended antibiotics for treatment and prophylaxis. Postgrad Med. 2004; 116: 49-52, 55-56, 59.
  131. Talan D.A., Abrahamian F.A., Moran G.J. et al. Clinical presentation and bacteriologic analysis of infected human bites presenting to an Emergency Department. Clin Infect Dis. 2003; 37: 1481-1489.
  132. Tentolouris N., Jude E., Smirnof I. et al. Methicillin-resistant Staphylococcus aureus: an increasing problem in a diabetic foot clinic. Diabet Med. 1999; 16: 767-771.
  133. Traunmuller F., Schintler M.V., Metzler J. et al. Soft tissue and bone penetration ability of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother. 2010; 65 (6): 1252-1257.
  134. Trent J.T., Kirsner R.S. Diagnosing necrotizing fasciitis. Adv Skin Wound Care. 2002; 15: 135-138.
  135. Turgeon A.F., Hutton B., Fergusson D.A. et al. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med. 2007; 146 (3): 193-203.
  136. US Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. October, 2013.
  137. Wagner A., Reike H., Angelkort B. Highly resistant pathogens in patients with diabetic foot syndrome with special reference to methicillin-resistant Staphylococcus aureus infections. Dtsch Med Worchenschr. 2001; 126 (48): 1353-1356.
  138. West M.A. Contemporary guide to surgical infections. Newtown: Handbooks in Health Care Co.; 2008.
  139. Weigelt J., Kaafarani H.M., Itani K.M. et al. Linezolid eradicates MRSA better than vancomycin from surgical- site infections. Am J Surg. 2004; 188: 760-766.
  140. Zervos M.J., Freeman K., Vo L. et al. Epidemiology and outcomes of complicated skin and sift tissue infections in hospitalized patients. J Clin Microbiol. 2012; 50: 238-245.
  141. Vayvada H., Demirdover C., Menderes A., Karaca C. Necrotizing fasciitis: diagnosis, treatment and review of the literature. Ulus Travma Acil Cerrahi Derg. 2012; 18 (6): 507-513.

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

Литература
На предыдущую главу Предыдущая глава
оглавление
Следующая глава

Table of contents

Данный блок поддерживает скрол*